2023 - Full Presentation Schedule
The Effect of Estrogen Deprivation Therapy on Sleep Quality, Quantity, and Efficiency in Breast Cancer Survivors
Abstract
Background: Existing research demonstrates that breast cancer survivors (BCS) report poor sleep as a side effect of estrogen deprivation therapy (EDT). Despite their potential importance, validated & objective measures of sleep are not yet widely incorporated into breast cancer research.
Purpose Statement: This study aimed to employ actigraph technology to capture real time objective sleep data in a population of BCS on EDT. In addition, surveys captured self-reported sleep data to allow comparison with objective sleep metrics, as well as to examine effects of EDT on sleep.
Methods: Twenty-two BCS (female) were provided a ReadiWatchTM (a wrist-worn actigraph) to assess objective sleep quality. Electronic surveys were administered at baseline, after one month, and at the end of the second month to assess perceived sleep and insomnia problems using Insomnia Severity Index (ISI) & Pittsburgh Sleep Quality Index (PSQI). Participants were able to access their sleep data on their mobile device using the ReadiWatchTM application after one month of ReadiWatchTM wear. Type of EDT was recorded for each participant.
Results: Actigraphy and subjective measures of sleep demonstrate that BCS on EDT have poor perceived and objectively measured sleep metrics. Objective sleep metrics were significantly different depending upon EDT, with those taking Anastrozole and Tamoxifen showing significantly decreased sleep quality and efficiency. No significant effects were seen for perceived sleep.
Conclusions: Data suggest that pharmacotherapy type may impact sleep quality and sleep quantity in BCS during treatment with EDT. Thus, this study’s findings may help inform future clinical conversations surrounding sleep in BCS as well as strategies for mitigation of sleep disturbances in this population.
The Effect of Estrogen Deprivation Therapy on Sleep Quality, Quantity, and Efficiency in Breast Cancer Survivors
CASB 118 - Graduate Health Sciences
Background: Existing research demonstrates that breast cancer survivors (BCS) report poor sleep as a side effect of estrogen deprivation therapy (EDT). Despite their potential importance, validated & objective measures of sleep are not yet widely incorporated into breast cancer research.
Purpose Statement: This study aimed to employ actigraph technology to capture real time objective sleep data in a population of BCS on EDT. In addition, surveys captured self-reported sleep data to allow comparison with objective sleep metrics, as well as to examine effects of EDT on sleep.
Methods: Twenty-two BCS (female) were provided a ReadiWatchTM (a wrist-worn actigraph) to assess objective sleep quality. Electronic surveys were administered at baseline, after one month, and at the end of the second month to assess perceived sleep and insomnia problems using Insomnia Severity Index (ISI) & Pittsburgh Sleep Quality Index (PSQI). Participants were able to access their sleep data on their mobile device using the ReadiWatchTM application after one month of ReadiWatchTM wear. Type of EDT was recorded for each participant.
Results: Actigraphy and subjective measures of sleep demonstrate that BCS on EDT have poor perceived and objectively measured sleep metrics. Objective sleep metrics were significantly different depending upon EDT, with those taking Anastrozole and Tamoxifen showing significantly decreased sleep quality and efficiency. No significant effects were seen for perceived sleep.
Conclusions: Data suggest that pharmacotherapy type may impact sleep quality and sleep quantity in BCS during treatment with EDT. Thus, this study’s findings may help inform future clinical conversations surrounding sleep in BCS as well as strategies for mitigation of sleep disturbances in this population.